Provided by Tiger Trade Technology Pte. Ltd.

Nurix Therapeutics

23.23
+1.024.59%
Volume:543.47K
Turnover:12.10M
Market Cap:2.40B
PE:-6.81
High:23.23
Open:22.04
Low:21.23
Close:22.21
52wk High:28.23
52wk Low:9.00
Shares:103.41M
Float Shares:74.11M
Volume Ratio:0.81
T/O Rate:0.73%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4102
EPS(LYR):-3.0514
ROE:-80.30%
ROA:-40.06%
PB:5.97
PE(LYR):-7.61

Loading ...

Nurix Therapeutics shareholders ratify PwC as auditor for fiscal 2026

Reuters
·
May 16

Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting

GlobeNewswire
·
May 15

Nurix Therapeutics (NRIX) Receives a Buy from Oppenheimer

TIPRANKS
·
May 13

Piper Sandler Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)

TIPRANKS
·
May 13

Nurix CEO Sands to join RBC Global Healthcare Conference fireside chat

Reuters
·
May 13

Nurix Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 13

BRIEF-Nurix Therapeutics Announces Bexobrutideg Oral Presentation

Reuters
·
May 13

Nurix to present updated Phase 1 data for BTK degrader bexobrutideg in CLL at EHA2026

Reuters
·
May 13

Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress

THOMSON REUTERS
·
May 13

Nurix CFO Hans van Houte disposes of common shares worth $233,463.29

Reuters
·
May 06

Nurix Chief Legal Officer Christine Ring disposes 8,148 shares worth $138,205

Reuters
·
May 05

Is Nurix’s Pan-Mutant BRAF Degrader Data Reshaping The Investment Case For Nurix Therapeutics (NRIX)?

Simply Wall St.
·
May 03

Nurix Chief Legal Officer Christine Ring sells 5,394 shares for $90,435

Reuters
·
May 02

Nurix Therapeutics Price Target Maintained With a $32.00/Share by HC Wainwright & Co.

Dow Jones
·
Apr 27

Nurix Therapeutics (NRIX) Receives a Buy from Piper Sandler

TIPRANKS
·
Apr 23

Nurix Therapeutics Price Target Maintained With a $26.00/Share by Needham

Dow Jones
·
Apr 23

Nurix reports early clinical NX-1607 target engagement data at AACR 2026

Reuters
·
Apr 22

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026

GlobeNewswire
·
Apr 22

Nurix Therapeutics (NRIX) Is Up 9.2% After Reporting Sharply Lower Q1 Revenue And Wider Loss

Simply Wall St.
·
Apr 18